159 related articles for article (PubMed ID: 36245381)
1. Effect of Aducanumab Approval on Willingness to Participate in Preclinical Alzheimer's Disease Trials.
Ritchie M; Witbracht M; Nuño MM; Hoang D; Gillen DL; Grill JD
J Alzheimers Dis; 2022; 90(3):1291-1300. PubMed ID: 36245381
[TBL] [Abstract][Full Text] [Related]
2. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
Vaz M; Silva V; Monteiro C; Silvestre S
Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
[TBL] [Abstract][Full Text] [Related]
3. Can we learn lessons from the FDA's approval of aducanumab?
Liu KY; Howard R
Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
[TBL] [Abstract][Full Text] [Related]
4. Aducanumab for Alzheimer's disease: A regulatory perspective.
Nisticò R; Borg JJ
Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
[TBL] [Abstract][Full Text] [Related]
5. Accelerated Approval of Aducanumab: Where Do We Stand Now?
Barenholtz Levy H
Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
[TBL] [Abstract][Full Text] [Related]
6. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
[TBL] [Abstract][Full Text] [Related]
7. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.
DiStefano MJ; Alexander GC; Polsky D; Anderson GF
J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210
[TBL] [Abstract][Full Text] [Related]
8. Aducanumab: First Approval.
Dhillon S
Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
[TBL] [Abstract][Full Text] [Related]
9. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
Yuksel JM; Noviasky J; Britton S
Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
[No Abstract] [Full Text] [Related]
10. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
Mukhopadhyay S; Banerjee D
J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
[TBL] [Abstract][Full Text] [Related]
11. Ignoring the Experts: Implications of the FDA's Aduhelm Approval.
Maulden A
Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585
[TBL] [Abstract][Full Text] [Related]
12. An insider's perspective on FDA approval of aducanumab.
Wang Y
Alzheimers Dement (N Y); 2023; 9(2):e12382. PubMed ID: 37215506
[TBL] [Abstract][Full Text] [Related]
13. [Aducanumab and Alzheimer's disease: a critical reflection.].
Vanacore N; Blasimme A; Canevelli M
Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
[TBL] [Abstract][Full Text] [Related]
14. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A
J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991
[TBL] [Abstract][Full Text] [Related]
15. Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria.
Togher Z; Dolphin H; Russell C; Ryan M; Kennelly SP; O'Dowd S
Int J Geriatr Psychiatry; 2022 Aug; 37(8):. PubMed ID: 35861223
[TBL] [Abstract][Full Text] [Related]
16. Controversial Approval of New Drug to Treat Alzheimer's Disease.
Aschenbrenner DS
Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
[TBL] [Abstract][Full Text] [Related]
17. Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.
Liu H; Li J; Ziegemeier E; Adams S; McDade E; Clifford DB; Cao Y; Wang G; Li Y; Mills SL; Santacruz AM; Belyew S; Grill JD; Snider BJ; Mummery CJ; Surti G; Hannequin D; Wallon D; Berman SB; Jimenez-Velazquez IZ; Roberson ED; van Dyck CH; Honig LS; Sanchez-Valle R; Brooks WS; Gauthier S; Galasko D; Masters CL; Brosch J; Hsiung GR; Jayadev S; Formaglio M; Masellis M; Clarnette R; Pariente J; Dubois B; Pasquier F; Bateman RJ; Llibre-Guerra JJ
J Prev Alzheimers Dis; 2024; 11(3):558-566. PubMed ID: 38706272
[TBL] [Abstract][Full Text] [Related]
18. Aducanumab: The first targeted Alzheimer's therapy.
Yang P; Sun F
Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
[TBL] [Abstract][Full Text] [Related]
19. Aducanumab for the treatment of Alzheimer's disease.
Tagliapietra M
Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541
[TBL] [Abstract][Full Text] [Related]
20. Making the Case for the Accelerated Withdrawal of Aducanumab.
Whitehouse PJ; Saini V
J Alzheimers Dis; 2022; 87(3):999-1001. PubMed ID: 35491796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
